Literature DB >> 30796069

Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.

Min Fong1, Stephen Boyle1, Naadir Gutta2.   

Abstract

We present a novel treatment protocol that was successful in the management of Hodgkin's-associated vanishing bile duct syndrome, a rare but serious complication of Hodgkin's lymphoma. We believe that publication of this treatment protocol and the rationale for its development will be of interest to anyone faced with treating this challenging condition. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (drugs and medicines); liver disease; malignant and benign haematology

Mesh：

Substances：

Year:  2019        PMID： 30796069      PMCID： PMC6388893          DOI： 10.1136/bcr-2018-227676

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  12 in total

1.  Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

Authors:  R S Benjamin; P H Wiernik; N R Bachur
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

2.  Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease.

Authors:  O M Crosbie; J P Crown; N P Nolan; R Murray; J E Hegarty
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

Review 3.  The effects of impaired liver function on the elimination of antineoplastic agents.

Authors:  G Koren; K Beatty; A Seto; T R Einarson; M Lishner
Journal:  Ann Pharmacother       Date:  1992-03       Impact factor: 3.154

4.  [Ductal regeneration in vanishing bile duct syndrome in Hodgkin's lymphoma].

Authors:  A Córdoba Iturriagagoitia; M Iñarrairaegui Bastarrica; E Pérez de Equiza; J M Zozaya Urmeneta; J M Martínez-Peñuela; R Beloqui Pérez
Journal:  Gastroenterol Hepatol       Date:  2005-05       Impact factor: 2.102

5.  Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.

Authors:  M C Perry; C G Moertel; A J Schutt; R J Reitemeier; R G Hahn
Journal:  Cancer Treat Rep       Date:  1976-09

6.  Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Authors:  Anas Younes; Joseph M Connors; Steven I Park; Michelle Fanale; Megan M O'Meara; Naomi N Hunder; Dirk Huebner; Stephen M Ansell
Journal:  Lancet Oncol       Date:  2013-11-15       Impact factor: 41.316

7.  Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.

Authors:  S C Piscitelli; K A Rodvold; D A Rushing; D A Tewksbury
Journal:  Clin Pharmacol Ther       Date:  1993-05       Impact factor: 6.875

8.  The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.

Authors:  H W Van den Berg; Z R Desai; R Wilson; G Kennedy; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 9.  Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review.

Authors:  Ari Ballonoff; Brian Kavanagh; Russell Nash; Harry Drabkin; James Trotter; Luciano Costa; Rachel Rabinovitch
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

Review 10.  Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.

Authors:  Delia Rota Scalabrini; Daniela Caravelli; Fabrizio Carnevale Schianca; Lorenzo D'Ambrosio; Francesco Tolomeo; Paola Boccone; Antonio Manca; Giovanni De Rosa; Annamaria Nuzzo; Massimo Aglietta; Giovanni Grignani
Journal:  BMC Res Notes       Date:  2014-08-14
View more
  1 in total

Review 1.  Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.

Authors:  Ioannis Papakonstantinou; Maria Kosmidou; Konstantina Papathanasiou; Epameinondas Koumpis; Eleni Kapsali; Haralampos Milionis; Theodoros P Vassilakopoulos; Alexandra Papoudou-Bai; Eleftheria Hatzimichael
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.